{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:57Z","timestamp":1792517997272,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L212012"],"award-info":[{"award-number":["L212012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128536","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:30:53Z","timestamp":1775154653000},"page":"128536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models"],"prefix":"10.1016","volume":"80","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20043049","article-title":"Impact of Coronavirus Disease COVID-19 on the Relationship between Healthcare Expenditures and Sustainable Economic Growth","volume":"20","author":"Vysochyna","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2026.128536_bb0010","author":"World Health Organization"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128536_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12101180","article-title":"What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era?","volume":"12","author":"Plans-Rubi\u00f3","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128536_bb0020","article-title":"Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis","volume":"371","author":"So","year":"2020","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"10351","key":"10.1016\/j.vaccine.2026.128536_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(22)00875-3","article-title":"Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA","volume":"vol. 400","author":"Mello","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.25259\/IJMR_750_2024","article-title":"Comparative efficacy of leading COVID-19 vaccines: a network meta-analysis","volume":"161","author":"Rai","year":"2025","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0035","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/vaccines10010050","article-title":"Evaluating the geographical accessibility and equity of COVID-19 vaccination sites in England","volume":"10","author":"Duffy","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13020187","article-title":"Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model","volume":"13","author":"Pritchard","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128536_bb0050","article-title":"Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases","volume":"6(1):60","author":"Kumar","year":"2021","journal-title":"npj Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128536_bb0055","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1473-3099(21)00567-3","article-title":"India\u2019s COVID-19 vaccination drive: key challenges and resolutions","volume":"21","author":"Choudhary","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128536_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-021-00909-1","article-title":"COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect Dis Poverty"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","article-title":"A comprehensive review of the global efforts on COVID-19 vaccine development","volume":"7","author":"Li","year":"2021","journal-title":"ACS Central Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128536_bb0070","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/09692290.2022.2074514","article-title":"Political economy of vaccine diplomacy: explaining varying strategies of China, India, and Russia\u2019s COVID-19 vaccine diplomacy","volume":"30","author":"Suzuki","year":"2023","journal-title":"Review of International Political Economy"},{"key":"10.1016\/j.vaccine.2026.128536_bb0075","author":"The People's Republic of China"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040495","article-title":"Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis","volume":"10","author":"Xiong","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128536_bb0085","article-title":"Cost-effectiveness analysis of vaccination against COVID-19 in China","volume":"11","author":"Zhou","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.128536_bb0090","doi-asserted-by":"crossref","first-page":"1099116","DOI":"10.3389\/fpubh.2023.1099116","article-title":"Cost-effectiveness analysis of COVID-19 screening strategy under China\u2019s dynamic zero-case policy","volume":"11","author":"Li","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.128536_bb0095","author":"China. TPsRo"},{"key":"10.1016\/j.vaccine.2026.128536_bb0100","author":"WHO"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","article-title":"Real-world COVID-19 vaccine effectiveness against the omicron BA.2 variant in a SARS-CoV-2 infection-naive population","volume":"29","author":"Lau","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2209201","article-title":"Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study","volume":"12","author":"Yan","year":"2023","journal-title":"Emerging microbes & infections"},{"key":"10.1016\/j.vaccine.2026.128536_bb0115","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1016\/j.wneu.2023.04.012","article-title":"Mechanical thrombectomy versus best medical management for acute ischemic stroke in elderly patients: a cost-effectiveness analysis","volume":"175","author":"Lim","year":"2023","journal-title":"World Neurosurg"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128536_bb0120","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.3390\/nu16193363","article-title":"A randomized controlled trial comparing loss versus gain incentives to improve adherence to an obesity treatment intervention in adolescents","volume":"16","author":"Siegel","year":"2024","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128536_bb0125","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128536_bb0130","author":"The People's Republic of China"},{"key":"10.1016\/j.vaccine.2026.128536_bb0135","author":"Heilongjiang Provincial Center for Disease Control and Prevention"},{"key":"10.1016\/j.vaccine.2026.128536_bb0140","author":"The People's Republic of China"},{"key":"10.1016\/j.vaccine.2026.128536_bb0145","author":"National Bureau of Statistics of China"},{"key":"10.1016\/j.vaccine.2026.128536_bb0150","article-title":"The health-related quality of life in Iranian patients with COVID-19","volume":"21(1):459","author":"Alinia","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jhqr.2022.01.001","article-title":"Health-related quality of life in patients recovered from COVID-19","volume":"37","author":"Ayuso Garc\u00eda","year":"2022","journal-title":"Journal of Healthcare Quality Research"},{"key":"10.1016\/j.vaccine.2026.128536_bb0160","article-title":"Health-related quality of life among patients recovered from COVID-19","volume":"59","author":"Huynh","year":"2022","journal-title":"Inquiry\u202f: A Journal of Medical Care Organization, Provision and Financing"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128536_bb0165","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40273-020-00954-y","article-title":"Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach","volume":"38","author":"Ochalek","year":"2020","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2026.128536_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2022.03.029","article-title":"Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States","volume":"119","author":"Li","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128536_bb0175","doi-asserted-by":"crossref","first-page":"1151311","DOI":"10.3389\/fimmu.2023.1151311","article-title":"Comparison of vaccination and booster rates and their impact on excess mortality during the COVID-19 pandemic in European countries","volume":"14","author":"Matveeva","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40258-023-00844-2","article-title":"Cost-effectiveness of the second COVID-19 booster vaccination in the USA","volume":"22","author":"Li","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/14760584.2024.2323133","article-title":"Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan","volume":"23","author":"Nagano","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128536_bb0190","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.vaccine.2023.01.075","article-title":"mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia","volume":"41","author":"Li","year":"2023","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128536_bb0195","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.jval.2023.03.630","article-title":"EE329 the value-based Price for a bivalent COVID-19 booster vaccine in the United Kingdom","volume":"26","author":"Kohli","year":"2023","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128536_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310427","article-title":"Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023","volume":"19","author":"Mahasing","year":"2024","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0205","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2214-109X(20)30452-6","article-title":"Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study","volume":"9","author":"Reddy","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1871","article-title":"Economic evaluation of vaccination against COVID-19: a systematic review","volume":"7","author":"Zeinab","year":"2024","journal-title":"Health Sci Reports"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1377\/hlthaff.2015.1088","article-title":"The social value of vaccination programs: beyond cost-effectiveness","volume":"35","author":"Luyten","year":"2016","journal-title":"Health Aff"},{"key":"10.1016\/j.vaccine.2026.128536_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jedc.2022.104306","article-title":"Optimal age-based vaccination and economic mitigation policies for the second phase of the covid-19 pandemic","volume":"140","author":"Glover","year":"2022","journal-title":"J Econ Dyn Control"},{"key":"10.1016\/j.vaccine.2026.128536_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126879","article-title":"Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: a review of methods and data inputs","volume":"51","author":"Smith","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128536_bb0230","doi-asserted-by":"crossref","unstructured":"Le TP, Conway E, Akpan E, et al. Cost-effective boosting allocations in the post-Omicron era of COVID-19 management medRxiv : The Preprint Server For Health Sciences 2023:2023.11. 14.23298536.","DOI":"10.1101\/2023.11.14.23298536"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128536_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012309","article-title":"Prioritising older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings","volume":"20","author":"Bouros","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128536_bb0240","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1080\/13696998.2023.2281083","article-title":"The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States","volume":"26","author":"Kohli","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2026.128536_bb0245","article-title":"A comprehensive comparison of DNA and RNA vaccines","volume":"115340","author":"Wang","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/vaccines13020187","article-title":"Cost-effectiveness of introducing Nuvaxovid to COVID-19 vaccination in the United Kingdom: a dynamic transmission model","volume":"13","author":"Pritchard","year":"2025","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0255","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/vaccines10040495","article-title":"Economic value of vaccines to address the COVID-19 pandemic in Hong Kong: a cost-effectiveness analysis","volume":"10","author":"Xiong","year":"2022","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128536_bb0260","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/vaccines12040434","article-title":"The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan","volume":"12","author":"Fust","year":"2024","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128536_bb0265","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/vaccines12121345","article-title":"Vaccine strategies against RNA viruses: current advances and future directions","volume":"12","author":"Hsiung","year":"2024","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/bioengineering9020072","article-title":"COVID-19 vaccines: an overview of different platforms","volume":"9","author":"Kudlay","year":"2022","journal-title":"Bioengineering"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128536_bb0275","doi-asserted-by":"crossref","first-page":"2300658","DOI":"10.1002\/biot.202300658","article-title":"Innovative translational platforms for rapid developing clinical vaccines against COVID-19 and other infectious disease","volume":"19","author":"Wang","year":"2024","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2026.128536_bb0280","author":"Jiaxing Center for Disease Control and Prevention ZP"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128536_bb0285","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bpa.2020.11.009","article-title":"Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives","volume":"35","author":"Kaye","year":"2021","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"10.1016\/j.vaccine.2026.128536_bb0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/nie.2021.25","article-title":"Productivity in UK healthcare during and after the Covid-19 pandemic","volume":"258","author":"Coyle","year":"2021","journal-title":"National Institute Economic Review"},{"key":"10.1016\/j.vaccine.2026.128536_bb0295","article-title":"Increased plastic pollution due to COVID-19 pandemic: challenges and recommendations","volume":"405","author":"Silva","year":"2021","journal-title":"Chem Eng J"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128536_bb0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23688","article-title":"Cost-effectiveness of 2023-2024 COVID-19 vaccination in US adults","volume":"8","author":"Prosser","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128536_bb0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15534","article-title":"Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2","volume":"8","author":"Miranda","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128536_bb0310","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.puhe.2024.07.029","article-title":"Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review","volume":"236","author":"Burch","year":"2024","journal-title":"Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:09Z","timestamp":1792515729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":62,"alternative-id":["S0264410X26003440"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128536","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128536"}}